Protein Kinase C enzyme “PKC”
Focused on one goal: Developing Novel Therapeutics to tame Cancer
Message: AACR presentation abstracts are online
Your Vote:
Did you know?
You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)
| Presentation Abstract | ||
| Abstract Number: | 2536 |
| Presentation Title: | Therapeutic testing of a novel PKC inhibitor GAP-107B8 on ovarian cancer cells |
| Presentation Time: | Monday, Apr 19, 2010, 2:00 PM - 5:00 PM |
| Location: | Exhibit Hall A-C, Poster Section 22 |
| Poster Section: | 22 |
| Poster Board Number: | 23 |
| Author Block: | Fu J. Yan1, Isabella Steffenson2, Kenneth Garson1, Barbara C. Vanderhyden1. 1Departments of Cellular and Molecular Medicine, University of Ottawa, and Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada; 2PharmaGap, Ottawa, ON, Canada |
| Abstract Body: | Background: Ovarian cancer is the most fatal gynaecologic disease in the western world. In 2009 in North America, an estimated 23,896 women will develop ovarian cancer and an estimated 15,24050 women will die from this disease. Current treatments are limited to surgery or chemotherapy, but the disease often recurs. Thus, the development of novel cancer therapeutics remains important. The protein kinase C (PKC) family of serine/threonine kinases is involved in cellular proliferation, differentiation, apoptosis and cell polarity. One PKC isoform, PKC iota, has recently been identified as a human oncogene and has been shown to be overexpressed in serous epithelial ovarian cancers and is thus a potential therapeutic target for ovarian cancer. Objective: We have tested a novel PKC inhibitor GAP-107B8 (PharmaGap Inc., Ottawa) in vitro on a panel of nine ovarian cancer cell lines to determine its potential to inhibit cell proliferation, proliferation in soft agar, and migration. Methods: Nine ovarian cancer cell lines were treated with three different concentrations of GAP-107B8 and then screened using high throughput assays to measure the proliferation of cells in adherent and anchorage independent (soft agar) cultures. The ability of cells to migrate in the presence of GAP-107B8 was also determined. Results: We observed significant reduction in cell proliferation in 6 of 9 ovarian cancer cell lines tested, including two cell lines resistant to the standard chemotherapy. GAP-107B8 inhibited cell proliferation by 30% to 79% compared with untreated cells, with more than 50% inhibition in 4 of 7 cell lines. Treatment with GAP-107B caused a reduction in growth in soft agar in 7 of the 9 cell lines tested in vitro. GAP-107B8 inhibited growth in soft agar by 50% to 94% compared with untreated cells, with 80% or greater inhibition in 6 of 7 cell lines. Finally, 5 of 8 cell lines tested showed significant inhibition of mobility following treatment with GAP-107B8. There was 50% or greater inhibition in all 5 cell lines compared with untreated cells. Conclusion: The novel PKC inhibitor GAP-107B8 displays good efficacy in vitro in suppressing several cancer cell characteristics in a variety of ovarian cancer cell lines. Further experiments are underway to investigate the therapeutic potential of GAP-107B8 in xenograft models of ovarian cancer. |
Loading...
Loading...
New Message
Please
login
to post a reply